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Background
With a number of preventive HIV vaccine candidates
under pre-clinical and early-phase human studies, it is cri-
tical to intensify efforts to identify and prepare populations
for potential efficacy trials. Willingness to participate
(WTP) in HIV vaccine trials in most at risk populations
for HIV infection is unknown especially in Sub-Saharan
Africa. We assessed WTP in a potential HIV-1 vaccine
efficacy trial population of fishing communities in Uganda.
Methods
A community-representative random sample of 2,200 indi-
viduals, 18-49 years was selected at baseline from 8 fishing
communities around Lake Victoria. After consent, data on
HIV risk behaviors and WTP in future HIV vaccine trials
were collected using a semi-structured questionnaire;
venous blood was collected for HIV serology using rapid
HIV tests as per the Uganda National algorithm.
Results
Fifty percent of respondents were females and a majority
(91%) had attained some level of education. Almost all
respondents, 89% (1,953/2,192) expressed WTP in future
HIV vaccine trials. Males were more willing to participate
than females (p<0.01). WTP was associated with aware-
ness of ongoing HIV vaccine research (p<0.01). Unwilling-
ness to participate was attributed mainly to perceived fear
of side effects (42%) and fear that the study vaccine may
cause HIV/AIDS (26.3%). The overall HIV prevalence was
26.7%, lower among those who responded positively to
WTP (26.8%) than those who did not (27.7%).
Conclusion
WTP in HIV vaccine trials in this population is high but
extensive education on HIV vaccine safety particularly on
vaccine induced side effects and false positivity will be
required in preparation for these trials. Because of the
high HIV prevalence, this population should be targeted
for future HIV vaccine trials.
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